Rituximab as a treatment option in a patient with rheumatoid arthritis and a history of malignancy—intracranial chondrosarcoma/osteochondroma—case based review

[1]  P. Higgins,et al.  Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. , 2019, The lancet. Gastroenterology & hepatology.

[2]  C. Turesson,et al.  Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis , 2018, Annals of Internal Medicine.

[3]  A. Regierer,et al.  Rheumatoid arthritis treatment in patients with a history of cancer , 2018, Current Opinion in Rheumatology.

[4]  Gautam Dutta,et al.  Pituitary fossa chondrosarcoma: An unusual cause of a sellar suprasellar mass masquerading as pituitary adenoma , 2018, Surgical neurology international.

[5]  G. Firestein.  Chapter 69 – Etiology and Pathogenesis of Rheumatoid Arthritis , 2017 .

[6]  J. Askling,et al.  Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden , 2016, British Medical Journal.

[7]  M. Hochberg,et al.  Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis , 2015, Arthritis Research & Therapy.

[8]  J. Askling,et al.  TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study , 2014, Annals of the rheumatic diseases.

[9]  W. Dixon,et al.  Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis , 2014, Annals of the rheumatic diseases.

[10]  J. Askling,et al.  Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden , 2013, BMJ : British Medical Journal.

[11]  C. Bombardier,et al.  Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety , 2012, The Journal of Rheumatology.

[12]  C. Bombardier,et al.  Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs , 2012, The Journal of Rheumatology.

[13]  D. Daikh,et al.  Updated recommendations for the treatment of rheumatoid arthritis: Another step on a long road , 2012, Arthritis care & research.

[14]  M. Neovius,et al.  Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. , 2011, Arthritis and rheumatism.

[15]  W. Dixon,et al.  SPECIAL ARTICLE: DRUG SAFETY IN THE RHEUMATIC DISEASES Influence of Anti–Tumor Necrosis Factor Therapy on Cancer Incidence in Patients With Rheumatoid Arthritis Who Have Had a Prior Malignancy: Results From the British Society for Rheumatology , 2022 .

[16]  G. Burmester,et al.  Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT , 2010, Arthritis research & therapy.

[17]  G. Thiele,et al.  The development of novel therapies for rheumatoid arthritis , 2008, Expert opinion on therapeutic patents.

[18]  J. Zwerina,et al.  Pathogenesis of Rheumatoid Arthritis: Targeting Cytokines , 2005, Annals of the New York Academy of Sciences.

[19]  C. Cobra,et al.  [Etiology and pathogenesis of rheumatoid arthritis. I. ]. , 1956, Revista brasileira de medicina.